Αρχική World News Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens in... World News Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens in Patients with Gastro-Oesophageal Adenocarcinoma Από Ogkologos - 26 Μαρτίου, 2025 1052 0 Facebook Twitter Google+ Pinterest WhatsApp Biomarker analyses from the CheckMate 649 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... 13 Μαρτίου, 2024 Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... 22 Ιουλίου, 2025 FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection... 25 Απριλίου, 2023 Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... 17 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... EU Cancer Mission and Partners Launch First Cancer Mission Forum for... ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in...